Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year

Rhea-AI Summary

Nutriband reported Q1 revenues of $408,532, highlighting a 219% YoY increase in sports tape sales via its Pocono Pharma subsidiary. The company is leveraging penetration pricing to secure deals with major brands like KT Tape, Reebok, Adidas, and New Balance.

In Q1, Nutriband completed an $8.4M private placement at $4 per share, bringing its cash position to $8,347,739 as of April 30, 2024.

The company is advancing its AVERSA line, targeting a Q1 2025 NDA filing for AVERSA Fentanyl, projected to achieve peak annual sales of $80-$200M. AVERSA Buprenorphine could reach up to $130M in annual sales.

Positive

• Q1 sports tape revenues increased by 219% year-over-year.
• Completed an $8.4M private placement, strengthening the balance sheet.
• Cash position as of April 30, 2024, was $8,347,739.
• Secured deals with major brands like KT Tape, Reebok, Adidas, and New Balance.
• Targeting Q1 2025 for NDA filing of AVERSA Fentanyl.
• Potential for AVERSA Fentanyl to reach peak annual sales of $80-$200M.
• Potential for AVERSA Buprenorphine to reach peak annual sales of up to $130M.

Negative

• Q1 revenues only $408,532, indicating modest overall earnings.
• Dependence on a single phase 1 clinical study for AVERSA Fentanyl's NDA could pose regulatory risks.
• AVERSA Fentanyl and Buprenorphine sales projections are speculative and not guaranteed.

Insights

Financial Analyst

The 219% increase in Q1 sports tape revenues for Nutriband Inc. (NTRB) is a significant milestone, particularly considering the company's penetration pricing strategy. This strategy aims to enter the market aggressively by offering lower prices to attract large contracts with well-known brands like Reebok and Adidas through license holders.

The completion of an $8.4M private placement and maintaining a strong cash position of $8.35M as of April 30, 2024, demonstrates solid financial management. However, investors should be aware of the potential dilution effect of new share issuance at $4 per share, which might not be favorable if the market price is higher.

The short-term financial outlook seems robust given the revenue surge and fresh capital. However, the company's reliance on few key clients for kinesiology tape could pose risks if these partnerships falter. Investors should monitor future revenue distribution and whether the company successfully diversifies its client base.

Medical Research Analyst

The development of AVERSA Fentanyl stands out. The company's plan to file an NDA with the FDA based primarily on a single phase 1 Human Abuse Potential clinical study is unusual. Typically, the FDA requires more extensive clinical trials (phases 2 and 3) before granting approval. This streamlined process could accelerate time-to-market but carries risks if the FDA finds the data insufficient.

If approved, AVERSA Fentanyl would be the first abuse-deterrent patch globally, a unique selling point that could drive significant sales. Peak annual sales estimates ranging from $80M to $200M reflect this potential. Similarly, AVERSA Buprenorphine's projected peak sales of $130M underscore the importance of these developments for the company's long-term growth.

Investors should recognize the potential regulatory hurdles and market acceptance challenges that could impact sales projections. Monitoring FDA updates and market reactions to abuse-deterrent technologies will be crucial.

ORLANDO, FL / ACCESSWIRE / June 3, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today reported Q1 revenues of $408,532 emphasizing its focus on expanding the company's Kinesiology Tape manufacturing services through its Pocono Pharma subsidiary. The Company has been focused on using penetration pricing to gain a foothold with some of the industry's largest brands and License holders such as KT Tape and Fit For Life Group, who hold licenses for major international brands such as Reebok, Adidas and New Balance.

The Company further strengthened its balance sheet in Q1 through the completion of an $8.4M Private placement with existing and new shareholders at a price of $4 per share. The Cash position of the company as of April 30, 2024 was $8,347,739.

Meanwhile in Q1, the Company has made further advancements in its development of AVERSA and it is maintaining a target of Q1 2025 for its NDA filing with the FDA. The Company recently updated shareholders about its development pathway for AVERSA Fentanyl reminding shareholders that its NDA will be primarily based on a single phase 1 Human Abuse Potential clinical study with no phase 2 or phase 3 clinical trials required prior to submission.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the World. AVERSA Fentanyl is estimated to have the potential to reach peak annual sales of $80-$200M, according to a market analysis report from Health Advances. AVERSA Buprenorphine, which is the company's second application for AVERSA has been further estimated to reach peak annual sales of up to $130M.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2023, filed April 26, 2023, the Forms 10-Q's filed subsequent to the Form 10-K in 2024, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

For more information, contact:

RedChip Companies, Inc.
Email: NTRB@Redchip.com
Phone: 1-407-644-4256

Address:
431 E Horatio Ave, Suite #100
Maitland, FL 32751
Nutriband Inc.
Phone: 407-377-6695
Email: Support@nutriband.com

SOURCE: Nutriband Inc.

View the original press release on accesswire.com

FAQ

What were Nutriband's Q1 2024 revenues?

Nutriband reported Q1 2024 revenues of $408,532.

How much did Nutriband's sports tape revenues grow?

Nutriband's sports tape revenues grew by 219% year-over-year.

What is Nutriband's cash position as of April 30, 2024?

Nutriband's cash position as of April 30, 2024, was $8,347,739.

When is Nutriband aiming to file the NDA for AVERSA Fentanyl?

Nutriband is aiming to file the NDA for AVERSA Fentanyl in Q1 2025.

What is the sales potential for AVERSA Fentanyl?

AVERSA Fentanyl has an estimated peak annual sales potential of $80-$200M.

What is the sales potential for AVERSA Buprenorphine?

AVERSA Buprenorphine has an estimated peak annual sales potential of up to $130M.

How much did Nutriband raise from the private placement in Q1 2024?

Nutriband raised $8.4M from its private placement in Q1 2024.